SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3548 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3548Aln-ang3 Another trial that regeneron is runningBiotechwantabe-last Wednesday
3547Dupi 20B in 2026? Seem a bit optimistic to do 20% penetration by 2026.Biotechwantabe-last Wednesday
3546From math stand points, 25% now is > than 30% 12 months early. However, from Miljenko Zuanic-April 29
3545Q1 presentation Check out slides6-8. Slowing growth from 30 to 25%. Not Biotechwantabe-April 26
3544Dupi okay? reuters.comFelix B-April 25
3543When you got $B in the bank, taking a few shots on goal is not bad. Alnylam iBiotechwantabe1April 25
3542I think that ALNY opted out for those two candidates, and probably for few more!Miljenko Zuanic-April 24
3541I would not read too much into their omission. Same omission in classic.clinicaBiotechwantabe-April 24
3540And ALNY was not at all mentioned in trial protocol??? ....hmmmm... It is not paMiljenko Zuanic-April 24
3539A Trial to Learn if REGV131-LNP1265 is Safe and Works to Help the Body Make ClotBiotechwantabe-April 23
3538Another Alnylam partnered program First in Human (FIH) Study of ALN-SOD in AdulBiotechwantabe-April 8
3537Another obesity patent. Treatment of obesity in subjects having variant nucleicBiotechwantabe-March 26
3536CRL Regeneron's blood cancer therapy faces setback as FDA raises trial conceBiotechwantabe-March 25
3535There is is another company testing a similar approach which should have full stFelix B1March 22
3534Some patent links: freepatentsonline.com freepatentsonline.comBiotechwantabe-March 12
3533Interesting. I've seen data showing rats lose a lot of muscle, along with faA.J. Mullen-March 12
35322025 looks good with lag3 and Il-33 potential. Starting 1 Muscle maintenanceBiotechwantabe-March 12
3531Thanks for that summary. 3 shots for new approvals and easier reimbursement comiA.J. Mullen-March 8
3530Upcoming dates: Odronextamab March 31. FDA Decision Eylea April 1. Jcode DuBiotechwantabe1March 8
35292024 guesstimate Dupi 11.588b +30% +3.5b. (COPD +?) Eylea 9.38b -5% -.5b. (Biotechwantabe-February 5
3528Sanofi q4 feb1/24Biotechwantabe1February 1
3527Conference call is tomorrow. Have they already announced Q4 earnings?A.J. Mullen-February 1
3526Dupi q4 €2.99B 31.3% growth.Biotechwantabe-February 1
3525No reason for Len or George to retire, George has the best drugs available AlzhBiotechwantabe-January 11
3524Sanofi report dupi, not REGN. So, 1.46 B (flat) sale is in line with expected, sMiljenko Zuanic-January 11
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):